1.	MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000669535, CRUK-CR0720-11, CRUK-MK-0752, EUDRACT-2008-004829-42, CR0720-11, NCT01098344
2.	A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 0646-027, NCT01243762
3.	Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 8669-049, NCT01295632